Altis Biosystems

Altis Biosystems is a private, pre-clinical stage company pioneering human-relevant intestinal epithelial cell models to bridge the gap between traditional cell lines, animal studies, and human clinical outcomes. Their core technology, the RepliGut® Systems, provides pharmaceutical and biotech researchers with scalable, reproducible platforms for assessing drug-induced GI toxicity, intestinal barrier function, inflammatory response, and drug disposition. By offering both kits and contract research services, Altis aims to de-risk drug development pipelines, accelerate timelines, and reduce reliance on animal models, positioning itself as a critical enabler in the growing market for predictive human biology models.

RepliGut® Systems: 2D planar in vitro models of the human intestine derived from primary human stem cells, designed to replicate gut epithelium physiology for pre-clinical drug discovery applications in toxicity, absorption, inflammation, and hormone research.

Altis competes with organ-on-a-chip companies (e.g., Emulate), 3D model providers (e.g., InSphero, STEMCELL Technologies), and the entrenched standards of Caco-2 cell lines and animal models. Its differentiation lies in offering a primary human stem cell-derived model in a scalable, user-friendly 2D planar format that balances physiological relevance with practical assay utility.